Analysis of pO2 in malignant ascites of patients with peritoneal dissemination of gastric cancer

Case Reports in Oncology

Volumn 3, Issue 3, 2010, Pages 344-348

  Emoto, Shigenobu ^a   Kitayama, Joji ^a,b   Yamaguchi, Hironori ^a   Ishigami, Hironori ^a   Kaisaki, Shoichi ^a   Nagawa, Hirokazu ^a  

^a THE UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

Gastric cancer; Malignant ascites; Peritoneal metastasis; PO2

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; VASCULOTROPIN;

ADULT; ANALYZER; ARTICLE; ASCITES; ASCITES FLUID; BLOOD GAS ANALYSIS; CANCER CHEMOTHERAPY; CANCER PATIENT; CARBON DIOXIDE TENSION; CARCINOMATOUS PERITONITIS; CLINICAL ARTICLE; FEMALE; HUMAN; HYPERTHERMIA; LAPAROTOMY; MALE; OXYGEN TENSION; PERITONEAL CAVITY; PERITONEUM METASTASIS; PH; PRIORITY JOURNAL; STOMACH CANCER; TUMOR CELL;

EID: 78751475638     PISSN: None     EISSN: 16626575     Source Type: Journal    
DOI: 10.1159/000321262     Document Type: Article

References (17)

1. Sugarbaker PH, Yonemura Y: Clinical pathway for the management of resectable gastric cancer with peritoneal seeding: best palliation with a ray of hope for cure. Oncology 2000;58:96-107.
2. Tan DS, Agarwal R, Kaye SB: Mechanisms of transcoelomic metastasis in ovarian cancer. Lancet Oncol 2006;7:925-934.
3. Liotta LA, Kohn EC: The microenvironment of the tumour-host interface. Nature 2001;411:375-379.
4. Fukumura D, Jain RK: Tumor microenvironment abnormalities: causes, consequences, and strategies to normalize. J Cell Biochem 2007;101:937-949.
5. Ishigami H, Kitayama J, Kaisaki S, Hidemura A, Kato M, Otani K, Kamei T, Soma D, Miyato H, Yamashita H, Nagawa H: Phase II study of weekly intravenous and intraperitoneal paclitaxel combined with s-1 for advanced gastric cancer with peritoneal metastasis. Ann Oncol 2010;21:67-70.
6. Sheckman P, Onderdonk AB, Bartlett JG: Anaerobes in spontaneous peritonitis. Lancet 1977;2:1223.
7. Gitlin N, Stauffer JL, Silvestri RC: The pH of ascitic fluid in the diagnosis of spontaneous bacterial peritonitis in alcoholic cirrhosis. Hepatology 1982;2:408-411.
8. Simmen HP, Blaser J: Analysis of pH and pO2 in abscesses, peritoneal fluid, and drainage fluid in the presence or absence of bacterial infection during and after abdominal surgery. Am J Surg 1993;166:24-27.
9. Noh SM: Measurement of peritoneal fluid pH in patients with non-serosal invasive gastric cancer. Yonsei Med J 2003;44:45-48.
10. Senger DR, Van de Water L, Brown LF, Nagy JA, Yeo KT, Yeo TK, Berse B, Jackman RW, Dvorak AM, Dvorak HF: Vascular permeability factor (VPF, VEGF) in tumor biology. Cancer Metastasis Rev 1993;12:303-324.
11. Zebrowski BK, Liu W, Ramirez K, Akagi Y, Mills GB, Ellis LM: Markedly elevated levels of vascular endothelial growth factor in malignant ascites. Ann Surg Oncol 1999;6:373-378.
12. Kobold S, Hegewisch-Becker S, Oechsle K, Jordan K, Bokemeyer C, Atanackovic D: Intraperitoneal VEGF inhibition using bevacizumab: a potential approach for the symptomatic treatment of malignant ascites? Oncologist 2009;14:1242-1251.
13. Hockel M SK, Aral B, Mitze M, Schaffer U, Vaupel P: Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 1996;56:4509-4515.
14. Brizel DM SG, Prosnitz LR, Scher RL, Dewhirst MW: Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 1997;38:285-289.
15. Vaupel P KD, Höckel M: Oxygen status of malignant tumors: pathogenesis of hypoxia and significance for tumor therapy. Semin Oncol 2001;28:29-35.
16. Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, Copeland LJ, Walker JL, Burger RA: Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006;354:34-43.
17. Tennant DA, Duran RV, Gottlieb E: Targeting metabolic transformation for cancer therapy. Nat Rev Cancer 2010;10:267-277.